Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

  1. Carey, L.A.
  2. Loirat, D.
  3. Punie, K.
  4. Bardia, A.
  5. Diéras, V.
  6. Dalenc, F.
  7. Diamond, J.R.
  8. Fontaine, C.
  9. Wang, G.
  10. Rugo, H.S.
  11. Hurvitz, S.A.
  12. Kalinsky, K.
  13. O’Shaughnessy, J.
  14. Loibl, S.
  15. Gianni, L.
  16. Piccart, M.
  17. Zhu, Y.
  18. Delaney, R.
  19. Phan, S.
  20. Cortés, J.
Journal:
npj Breast Cancer

ISSN: 2374-4677

Year of publication: 2022

Volume: 8

Issue: 1

Type: Article

DOI: 10.1038/S41523-022-00439-5 GOOGLE SCHOLAR lock_openOpen access editor